50% of cutaneous T-cell lymphoma patients treated with 300mg IV infusion achieved objective response lasting for greater than four months (ORR4)Evidence of disease stabilization in five adult T-cell l...
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...
BOULDER, Colo., Dec. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...
BOULDER, Colo., Dec. 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...
Continued advancements of three clinical stage microRNA-targeted product candidates currently being evaluated for multiple potential indications in four clinical trialsGlobal Phase 2 SOLAR clinical tr...
